Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lm-LLO-TT and Gemcitabine in Advanced Pancreatic Cancer
NCT07828236Phase 1Not yet recruiting
- Sponsor
- Loki Therapeutics
- Start
- Oct 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of LM-LLO-TT in pancreatic ductal adenocarcinoma (PDAC) (3 arms), sponsored by Loki Therapeutics. Primary endpoint: Safety and tolerability at Day 45. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
LM-LLO-TT
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07828236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07828236.